San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Less than two months after agreeing to partner with Hims & Hers, Novo Nordisk accused the telehealth company of putting patient safety at risk through “deceptive” marketing and selling a knockoff ...

HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...